41 results
8-K
EX-99.1
BIVI
BioVie Inc - Ordinary Shares
11 Mar 24
BioVie Announces Pipeline Update and Near-Term Clinical Priorities
5:00pm
-item cognitive subscale of the Alzheimer’s Disease Assessment Scale (lower is improvement); ADCOMS = Alzheimer’s Disease Composite Score (lower
424B5
BIVI
BioVie Inc - Ordinary Shares
4 Mar 24
Prospectus supplement for primary offering
5:28pm
endpoints looking at cognition using the Alzheimer’s Disease Assessment Scale-Cognitive Scale (ADAS-Cog 12) and function using the Clinical Dementia … endpoints looking at cognition using the Alzheimer’s Disease Assessment Scale-Cognitive Scale (ADAS-Cog 12) and function using the Alzheimer’s Disease
424B5
BIVI
BioVie Inc - Ordinary Shares
1 Mar 24
Prospectus supplement for primary offering
5:27pm
Assessment Scale-Cognitive Scale (ADAS-Cog 12) and function using the Clinical Dementia Rating-Sum of Boxes (CDR-SB). Patients were randomly assigned, 1 … at cognition using the Alzheimer’s Disease Assessment Scale-Cognitive Scale (ADAS-Cog 12) and function using the Alzheimer’s Disease Cooperative Study
8-K
EX-99.1
BIVI
BioVie Inc - Ordinary Shares
1 Mar 24
Other Events
9:40am
Disorders, August 27-31, 2023 in Copenhagen, Denmark
ADAS-Cog12 = 12-item cognitive subscale of the Alzheimer’s Disease Assessment Scale (lower
424B3
lzex9j datwr0nkmp7
19 Jan 24
Prospectus supplement
5:00pm
8-K
EX-99.1
bqv80q0hte
29 Nov 23
BioVie Announces EfficacyData from Phase 3 Trial of NE3107 in Patientswith Mild to Moderate Alzheimer’s Disease
8:20am
8-K
EX-99.1
vs5d9i
25 Oct 23
Other Events
1:04pm
424B3
a4n2wkm
28 Aug 23
Prospectus supplement
8:25pm
424B5
ghmizyim
23 Dec 22
Prospectus supplement for primary offering
5:15pm
424B5
2u82ouqp7jelump xgm
14 Dec 22
Prospectus supplement for primary offering
8:25pm
8-K
EX-99.2
pld74aylcdm xsg7pb6
7 Dec 22
Regulation FD Disclosure
4:15pm
8-K
EX-99.1
9u5zf9
6 Dec 22
BioVie Announces Positive Results for NE3107 in Parkinson’s and Alzheimer’s Phase 2 Trials
6:05am
8-K
EX-99.2
1xtu9 nr0z54awe
6 Dec 22
BioVie Announces Positive Results for NE3107 in Parkinson’s and Alzheimer’s Phase 2 Trials
6:05am